BR112021011386A2 - Deutetrabenazina para o tratamento da discinesia na paralisia cerebral - Google Patents

Deutetrabenazina para o tratamento da discinesia na paralisia cerebral Download PDF

Info

Publication number
BR112021011386A2
BR112021011386A2 BR112021011386-0A BR112021011386A BR112021011386A2 BR 112021011386 A2 BR112021011386 A2 BR 112021011386A2 BR 112021011386 A BR112021011386 A BR 112021011386A BR 112021011386 A2 BR112021011386 A2 BR 112021011386A2
Authority
BR
Brazil
Prior art keywords
patient
baseline
deutetrabenazine
score
study
Prior art date
Application number
BR112021011386-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Juha-Matti Savola
Mark Forrest GORDON
Frank Schneider
Original Assignee
Auspex Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals, Inc filed Critical Auspex Pharmaceuticals, Inc
Publication of BR112021011386A2 publication Critical patent/BR112021011386A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021011386-0A 2018-12-13 2019-12-13 Deutetrabenazina para o tratamento da discinesia na paralisia cerebral BR112021011386A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779232P 2018-12-13 2018-12-13
US62/779,232 2018-12-13
US201962801450P 2019-02-05 2019-02-05
US62/801,450 2019-02-05
PCT/US2019/066150 WO2020123900A1 (en) 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Publications (1)

Publication Number Publication Date
BR112021011386A2 true BR112021011386A2 (pt) 2021-08-31

Family

ID=69173404

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021011386-0A BR112021011386A2 (pt) 2018-12-13 2019-12-13 Deutetrabenazina para o tratamento da discinesia na paralisia cerebral

Country Status (15)

Country Link
US (3) US11324732B2 (cg-RX-API-DMAC7.html)
EP (1) EP3893876A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022519007A (cg-RX-API-DMAC7.html)
KR (1) KR20210114946A (cg-RX-API-DMAC7.html)
CN (1) CN113395966A (cg-RX-API-DMAC7.html)
AU (1) AU2019395250A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021011386A2 (cg-RX-API-DMAC7.html)
CA (1) CA3123393A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001554A1 (cg-RX-API-DMAC7.html)
IL (1) IL283920A (cg-RX-API-DMAC7.html)
MX (1) MX2021007063A (cg-RX-API-DMAC7.html)
SG (1) SG11202106344SA (cg-RX-API-DMAC7.html)
TW (1) TWI784220B (cg-RX-API-DMAC7.html)
WO (1) WO2020123900A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104786B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519007A (ja) * 2018-12-13 2022-03-18 オースペックス ファーマシューティカルズ インコーポレイテッド 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン
US20240197714A1 (en) * 2021-04-15 2024-06-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
JP2024514873A (ja) * 2021-04-15 2024-04-03 ニューロクライン バイオサイエンシーズ,インコーポレイテッド デューテトラベナジンおよびcyp2d6阻害剤の併用投与のための方法
WO2024090922A1 (ko) 2022-10-24 2024-05-02 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591615A (en) * 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2015200243B2 (en) * 2009-06-24 2016-09-29 Egalet Ltd Controlled release formulations
US20120003330A1 (en) * 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態
PL3265085T3 (pl) * 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
TWI772382B (zh) * 2017-03-15 2022-08-01 美商奧斯拜客斯製藥有限公司 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途
JP2022519007A (ja) * 2018-12-13 2022-03-18 オースペックス ファーマシューティカルズ インコーポレイテッド 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン

Also Published As

Publication number Publication date
EP3893876A1 (en) 2021-10-20
JP2022519007A (ja) 2022-03-18
US11324732B2 (en) 2022-05-10
CA3123393A1 (en) 2020-06-18
ZA202104786B (en) 2023-12-20
CN113395966A (zh) 2021-09-14
TWI784220B (zh) 2022-11-21
KR20210114946A (ko) 2021-09-24
US20200188371A1 (en) 2020-06-18
MX2021007063A (es) 2021-12-10
IL283920A (en) 2021-07-29
WO2020123900A1 (en) 2020-06-18
US20220409597A1 (en) 2022-12-29
SG11202106344SA (en) 2021-07-29
TW202034917A (zh) 2020-10-01
CL2021001554A1 (es) 2022-02-11
US20240082225A1 (en) 2024-03-14
AU2019395250A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
US20250302851A1 (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
Pavuluri et al. Divalproex sodium for pediatric mixed mania: a 6‐month prospective trial
ES2879631T3 (es) Pridopidina para el tratamiento de la enfermedad de Huntington
Moise et al. Psychiatric symptoms associated with brain tumors: a clinical enigma
US20220409597A1 (en) Methods for the treatment of dyskinesia in cerebral palsy
Connor et al. Neuroleptic-related dyskinesias in children and adolescents
JP2026050474A (ja) Nmda拮抗薬の副作用の低減
AU2019384157A1 (en) Gaboxadol for reducing risk of suicide and rapid relief of depression
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
TW202102219A (zh) 使用氘化右旋美沙芬(dextromethorphan)及奎尼丁(quinidine)治療精神分裂症之負面徵候之方法
US11369603B2 (en) Use of a H3R inverse agonist for the treatment of shift work disorder
JP2009515952A (ja) 制御放出性製剤のクエチアピン
Babu et al. Birth weight and use of olanzapine in pregnancy: a prospective comparative study
CN118555956A (zh) 用于治疗难治性抑郁症的赛洛西宾和辅助血清素再摄取抑制剂
AU2019306092A1 (en) Compositions and methods for treating autism
EA044015B1 (ru) Дейтетрабеназин для лечения дискинезии при церебральном параличе
TW202302109A (zh) 認知損傷之治療
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
CN114096251A (zh) 用于治疗睡眠问题的莱博雷生
Blay et al. A case of obsessive-compulsive disorder responding to duloxetine
Rajab et al. The use of chloral hydrate sedation in pediatric strabismus outpatient clinic
Aggarwal et al. Akathisia associated with mianserin
Swart The efficacy and safety of intravenous sedation in children under the age of 10 years
Bebchuk et al. Neurobiology of social phobia
Chan et al. Basics of Psychopharmacological Management

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements